Brought to you by 
Boehringer Ingelheim, Pfizer to co-promote Spiriva
18 Feb 2015
Executive Summary
Boehringer Ingelheim and Pfizer will globally co-promote BI's Spiriva (tiotropium), a once daily, inhaled bronchodilator to treat chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. Smoking mostly causes the disorder, which causes permanent damage to lung tissue. According to a source from BI, the term of the contract will probably be less than eight years.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com